Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic.
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , Extensively hydrolyzed ... milk   Cow milk protein allergy (CMPA) is the leading ... Until now, it has been managed by eliminating milk ... shown that it is possible to help build of ... of children during the first year of life by ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... the basis of test type, technology, product, and ... register the highest growth rate in the newborn ... This high growth is attributed to various nations ... is a fundamental instrument used for expanded newborn ...
(Date:10/30/2014)... Hospital stretchers are apparatus used to ... inside or outside of medical infrastructure premises. In ... used for several specialized functions such as hospital ... The hospital stretchers market report studies ... potential of hospital stretchers globally. The hospital stretchers ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
(Date:10/30/2014)... Don Allred Insurance, a leading provider of ... North Carolina residents, is excited to announce the Grand ... Mall. The new branch has been up and running ... all facets of the insurance selection process from quote ... Allred couldn’t be happier with the timing of this ...
(Date:10/30/2014)... Five months after their expansion, the ... announces new branding and a website to accompany their ... David Mepham’s promotion to name partner earlier this year, ... include Mepham’s name and better reflect their combined litigation ... the decision to implement new branding reflects Hodgkinson Street ...
(Date:10/30/2014)... 2014 Paramount Rx, a full-service prescription ... efforts to help people save money through its innovative ... for prescription drugs in the new health care system, ... to bridge the relationship between consumers, businesses and the ... challenges people face today with medical costs is the ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. ... with prostate cancer who also have certain heart problems may ... new study suggests. , , The therapy in question is called ... reduce levels of male hormones to prevent the growth of ... research, this hormone therapy was linked to triple the risk ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... Ebola outbreak in Liberia -- one of three West African ... Health Organization officials said Wednesday. Dr. Bruce Aylward, WHO,s ... number of burials in Liberia and no increase in laboratory-confirmed ... push to tame the epidemic may be making some progress, ...
Breaking Medicine News(10 mins):Health News:Allred Insurance Satellite Office Grand Opening 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3
... better known for their close association to fishes has ... ,Dietary intake of omega 3 fatty acids such ... may curb the growth of breast cancer cells, ... of Cancer., ,Min Wu and colleagues at Methodist ...
... study in USA to see if the procedures of ... ,The study will enroll of more than 16,000 ... be safely performed in smaller, community hospitals, easing access ... the first study patients in early fall 2005. ...
... cancer remain the most feared diseases all around the ... inhaler, potentially offering adult diabetics an alternative to injections// ... to be approved by the FDA. ,If approved, ... to the insulin injections taken by millions worldwide. The ...
... people may accelerate the heart conditions by releasing the levels ... of 32 people with heart failure, the 14 patients who ... this protein in their blood. ,The protein, tumor necrosis ... of proteins called cytokines, chemical messengers that are mobilized when ...
... Research suggests that 25% of the MRSA infections in the ... the hospital. The research was published in the latest ... many sites; one serious form of infection is that in ... scheme counts MRSA bacteremia by hospital trust, but it has ...
... doctors of American Origin are helping out the victims from ... members of the American Association of Physicians of Indian Origin// ... US who number over 25,000 - have volunteered their services ... Mississippi and Alabama. ,The volunteers hail from almost all ...
Cached Medicine News:Health News:Exubera could mean the end of an insulin injection era for diabetics 2Health News:Indian doctors in America help Katrina victims 2
... from the latest 60 series bronchoscopes., ... range, focussing on providing clinicians with ... Olympus has a impressive range of ... in the respiratory tract to meet ...
Fujinon's standard fiberoptic bronchoscope is fully submersible and offers a large image for more comfortable and efficient observation....
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
... The BF-1T40 has been designed with a ... in therapeutic applications. This permits the selection ... those for electrosurgical procedures. In addition, this ... field of view and a bright, high-resolution ...
Medicine Products: